Aileron Therapeutics, Inc. stock is up 24.72% since 30 days ago. The next earnings date is Mar 18, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 28.57% of the previous 6 December’s closed higher than November. 100% of analysts rate it a buy.
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. Company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma.